Clinical study to evaluate the potential of ORIC’s novel
glucocorticoid receptor antagonist to be used in combination with
Abraxane®
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–ORIC Pharmaceuticals, a privately held, clinical-stage oncology company
focused on the discovery and development of novel therapies against
treatment-resistant cancers, announced the initiation of patient dosing
in a Phase 1b clinical study of ORIC-101 in combination with
nab-paclitaxel (marketed as Abraxane® by Celgene Corporation)
in patients with advanced solid tumors.
“Phase 1b initiation of ORIC-101
in patients with cancer represents a major milestone for ORIC,” said
Jacob Chacko, MD, Chief Executive Officer. “ORIC’s in-house discovery
team, based on findings originating from Dr. Charles Sawyers’
laboratory, identified and developed a selective and potent oral
inhibitor of the glucocorticoid receptor (GR), which has been linked to
treatment resistance to multiple classes of anti-cancer therapeutics
across a variety of solid tumors. Building on our recently completed
study in healthy volunteers, we are looking forward to this first
clinical study of ORIC-101 through which we hope to begin demonstrating
the potential of ORIC-101 to benefit patients with cancer.”
The Phase 1b trial is a dose finding, multi-center, open label study
designed to evaluate the safety, pharmacokinetics, pharmacodynamics and
clinical efficacy of ORIC-101 combined with nab-paclitaxel in patients
with advanced solid tumors. Following identification of the recommended
Phase 2 dose of ORIC-101 in combination with nab-paclitaxel, ORIC
intends to enroll patients into expansion cohorts in selected tumor
types based upon GR levels using its proprietary immunohistochemistry
assay.
Subsequent to this initial Phase 1b study of ORIC-101 in combination
with nab-paclitaxel, ORIC also plans to initiate additional Phase 1b
studies of ORIC-101 in combination with other anti-cancer agents,
including with androgen receptor modulators in patients with advanced
prostate cancer and with immunotherapy agents. Ongoing and planned
clinical studies of ORIC-101 are supported by research conducted at ORIC
and recent clinical studies of ORIC-101 in healthy volunteers, which
demonstrated that ORIC-101 appeared to be safe and well-tolerated, with
a pharmacokinetic profile sufficient for oral once-daily dosing and
pharmacodynamic activity suggestive of effective target engagement.
“Despite many new anti-cancer therapies, resistance remains a
significant barrier to improved outcomes in most patients with advanced
cancers,” said Pratik Multani, MD, Chief Medical Officer. “We are
excited to evaluate the potential of ORIC-101 to overcome what we
believe to be a major mechanism of resistance, overexpression of GR.
This first clinical trial kicks off a robust clinical development plan
to evaluate ORIC-101, the first of our programs to enter the clinic, in
combination with multiple classes of anti-cancer agents across various
indications that span the range of solid tumor malignancies.”
Further details about the clinical study are available at
ClinicalTrials.gov (NCT03928314).
About ORIC Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology
company focused on making cancer treatments more effective by addressing
mechanisms of resistance. ORIC’s lead program, ORIC-101, is a potent and
selective small molecule antagonist of the glucocorticoid receptor,
which has been linked to treatment resistance to multiple classes of
anti-cancer therapeutics across a variety of solid tumors. ORIC’s
pipeline also includes an orally-available small molecule inhibitor of
CD73, as well as other undisclosed programs targeting mechanisms of
oncology therapy resistance. ORIC’s scientific founders are Charles
Sawyers, MD, and Scott Lowe, PhD, who have long records of discovering
novel targets in cancer that have led to innovative treatments. The
company has assembled strong leadership and scientific teams and a board
with extensive experience in drug development and financing. ORIC is
funded by leading biotechnology investors, including The
Column Group, Topspin
Partners, OrbiMed,
EcoR1,
Fidelity, Foresite
and others. ORIC is headquartered in South San Francisco, California.
Contacts
For more information, please contact:
Krys Corbett
650-388-5622
info@oricpharma.com
http://oricpharma.com/